Opinion

Video

The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, discusses the efficacy and adverse effects of fedratinib, highlighting its potential in the second-line setting for patients resistant to ruxolitinib, with updates from FREEDOM-2 emphasizing manageable gastrointestinal tolerability concerns.

Related Videos
Michael R. Grunwald, MD, FACP
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Daniel DeAngelo, MD, PhD
Francine Foss, MD
Daniel DeAngelo, MD, PhD
Daniel DeAngelo MD, PhD, professor, medicine, Harvard Medical School; physician, chief, Division of Leukemia, Dana-Farber Cancer Institute
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Related Content
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Pacritinib in myelofibrosis Image credit: Ifti Digital– stock.adobe.com
November 13th 2024

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis